A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 257
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : OAB
Long Form : overactive bladder syndrome
No. Year Title Co-occurring Abbreviation
2022 Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. PPBC
2022 Home-based transcutaneous tibial nerve stimulation for overactive bladder syndrome: a randomized, controlled study. QoL, TPTNS, UUI, ZIDA
2022 Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial. ---
2022 Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder. ICIQ-SF, PGI-I
2022 Overactive bladder syndrome and sexual dysfunction in women with fibromyalgia and their relationship with disease severity. FIQR, FM, FSFI, OABSS, PDQ, WPI
2022 Physiotherapeutic assessment and management of overactive bladder syndrome: a case report. ---
2022 Predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence. MUS, SUI
2022 TGR5 agonists induce peripheral and central hypersensitivity to bladder distension. DRG, IC/BPS
2022 Total trans-obturator tape (TOT) removal; a case series including pain and urinary continence outcomes. IQR, MUT, SUI, TOT
10  2021 Acupuncture in addition to standard conservative treatment for overactive bladder; a feasibility trial for a randomized controlled study. RCT
11  2021 Anatomical and functional outcomes of uterus preservation and pelvic organ prolapse repair with vaginal trocar-less mesh kit (Endofast): A retrospective study of 239 patients. SUI
12  2021 Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome. CUA, NHS, QALYS
13  2021 Current Management of Post-radical Prostatectomy Urinary Incontinence. PFMT
14  2021 Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review. ---
15  2021 Effectiveness and safety of tibial nerve stimulation versus anticholinergic drugs for the treatment of overactive bladder syndrome: a meta-analysis. ACDs, MDs, ORs, TNS
16  2021 Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study. LURN, QST
17  2021 Intravaginal 6.5mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. GSM, QoL, VHI, VVA
18  2021 Overactive bladder syndrome in nulliparous female university students: prevalence and risk factors including waterpipe smoking. BMI, LUTS, UUI, WP
19  2021 Overactive bladder syndrome is associated with detrusor overactivity and abnormal voiding pattern in nulliparous women. CS, DO, MUCP, NP, NSD
20  2021 Peroneal Electric Transcutaneous NeuroModulation (eTNM®): A Novel Method for the Treatment of the Overactive Bladder. BFS, eTNM, EU, FDA, Peroneal eTNM
21  2021 Prevalence and predictors of nocturnal polyuria in females with overactive bladder syndrome. NP, NPi
22  2021 Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome. PTNS, TTNS
23  2021 [Charasteristics of the treatment of urinary disorders in postmenopausal women]. FSFI, MMSE, OABSS
24  2020 An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction. FCUR, SNM
25  2020 Association of Severity of Lower Extremity Arterial Disease and Overactive Bladder Syndrome: A Cross Sectional Study. ---
26  2020 Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. ---
27  2020 Comparison of parasacral transcutaneous electrical stimulation and transcutaneous posterior tibial nerve stimulation in women with overactive bladder syndrome: A randomized clinical trial. ISI, KHQ, OAB-V8, PS, PTN
28  2020 Comparison of vascularization and overall perfusion of the bladder wall between women with and without overactive bladder syndrome. ---
29  2020 Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome. PTNS-MT
30  2020 Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. NGF
31  2020 Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome? ADs, AEs, OABSS, RCTs
32  2020 Is There a Link Between Carotid Atherosclerosis and Idiopathic Overactive Bladder Among Women with Metabolic Syndrome? CP, IMT, MetS
33  2020 Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder. MMAS, OABq
34  2020 Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study. SNM
35  2020 Prevalence, Bother and Treatment Behavior Related to Lower Urinary Tract Symptoms and Overactive Bladder among Cardiology Patients. LUTS
36  2020 Recent advances in managing overactive bladder. ---
37  2020 Regional brain atrophy in overactive bladder syndrome: a voxel based morphometry study. FDR, GMV, OABSS, VBM
38  2020 Risk factors for mild depression in older women with overactive bladder syndrome-A cross sectional study. GDS-15
39  2020 Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications. ---
40  2020 Update on non-invasive treatment for female overactive bladder. ---
41  2020 Vaginal laser for overactive bladder syndrome. GSM
42  2019 A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being. FSD, SN, TES, UTI
43  2019 A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naive Patients With Overactive Bladder Syndrome. AE, PTNM
44  2019 Abnormal Brain Functional Connectivity Strength in the Overactive Bladder Syndrome: A Resting-State fMRI Study. FCS
45  2019 Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study. ACB, GDS, MoCA
46  2019 Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). ---
47  2019 Effects of biofeedback-based sleep improvement program on urinary symptoms and sleep patterns of elderly Korean women with overactive bladder syndrome. BBSI
48  2019 Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and beta3-adrenoceptor agonists. OABSS, VEL, VHIS
49  2019 Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome. IC/PBS
50  2019 Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation. GRA, NOVD
51  2019 The impact of different intensities of exercise on body weight reduction and overactive bladder symptoms- randomised trial. BFP, BMI, OAB-q, PPIUS, PRAF, VFA
52  2019 The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study. ---
53  2019 Urinary metabolomics predict the severity of overactive bladder syndrome in an aging female population. ROC
54  2019 Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry. OR
55  2019 [Female urinary incontinence: diagnosis and treatment]. SUI, UI, UUI
56  2018 A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome. CAM, OAB-q SF, PGI-I, PPIUS, SS
57  2018 Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study. HADS, ICIQ, LUTS, NOR, QoL, SF-36, SNM
58  2018 Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate. beta3-AR, GPR91, SMC
59  2018 How long do we have to treat overactive bladder syndrome (OAB)? A questionnaire survey of Canadian urologists and gynecologists. ---
60  2018 Intravesical electrical stimulation treatment for overactive bladder: An observational study. IVES, PFDI, PFIQ, PGI-I, UUI, VAS
61  2018 Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment? ---
62  2018 Medical treatment of female overactive bladder syndrome and treatment-related effects. ---
63  2018 Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand? ---
64  2018 Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? UUI, VHI, VVA
65  2018 Pelvic Floor Muscle Training With Or Without Tibial Nerve Stimulation and Lifestyle Changes Have Comparable Effects on The Overactive Bladder. A Randomized Clinical Trial. LSR, PFMT, TPTNS
66  2018 Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. PTNS, UUI
67  2018 Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms. OR, SUI, UI, UUI
68  2018 The development of a patient-reported outcome measure for real-time symptom assessment in a population with functional urologic complaints-A focus group study. ESM, PROM
69  2018 The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. LURN, LUTS, MRI, NIST, QST
70  2018 The prevalence and risk factors of nocturia in China, South Korea, and Taiwan: results from a cross-sectional, population-based study. HADS, IPSS, LUTS
71  2018 [Efficacy of the percutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms]. PTNS
72  2017 A case controlled study examining the bladder microbiome in women with Overactive Bladder (OAB) and healthy controls. ---
73  2017 Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle. AUM, MUI, SUI, UUI, VD
74  2017 Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis. OD
75  2017 Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study. ---
76  2017 Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. ---
77  2017 Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. PTNS
78  2017 Indirect treatment comparison (ITC) of medical therapies for an overactive bladder. ITC, RCT
79  2017 Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy? ---
80  2017 No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy. ---
81  2017 No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum. GRADE
82  2017 Novel biomarkers of overactive bladder syndrome. BDNF, CRP, NGF
83  2017 Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management. SUI, UUI
84  2017 Percutaneous Tibial Nerve Stimulation Therapy for Overactive Bladder Syndrome: Clinical Effectiveness, Urodynamic, and Durability Evaluation. PTNS
85  2017 Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. PTNS
86  2017 Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. ---
87  2017 Perspectives for the pharmacological treatment of overactive bladder syndrome. ---
88  2017 Re: Sheng W, Zhang H, Kirschner-Hermanns R. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis. Neurourol Urodyn. 2017;9999:1-8. doi: 10.1002/nau.23210. ELISA, NGF
89  2017 Stimulus-associated urinary urges in overactive bladder syndrome. ---
90  2017 Succinate, increased in metabolic syndrome, activates GPR91 receptor signaling in urothelial cells. NO, PGE2, SMCs
91  2017 Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study. MMSE
92  2017 Urogynecological conditions associated with overactive bladder symptoms in women. BOO, LUTS, NGB, POP, SUI, UTI
93  2017 [Food, diet and dietetic in treatment of urinary tract dysfunctions. A review]. ---
94  2016 A minimum of 1-year follow-up for MiniArc single incision slings compared to Monarc transobturator slings: An analysis to evaluate durability of continence and medium-term outcomes. CR, OC, SF, SIS, SUI, TOT
95  2016 An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude. HCl
96  2016 Biofeedback as a first-line treatment for overactive bladder syndrome refractory to standard urotherapy in children. DV, LUTD, LUTSS
97  2016 Does central sensitization help explain idiopathic overactive bladder? ---
98  2016 Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. GRA, PVR, VE
99  2016 Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. PR
100  2016 Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014. UPV